Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





New Focus in Project Portfolio of Gerresheimer Subsidiary Sensile Medical

19.11.2019
Dusseldorf, Germany (ots/PRNewswire) - Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the Swiss biopharma­ceutical company SQ Innovation AG for the development, market launch and mass production of a micro pump for the treatment of edema in heart failure. Sanofi, on the other hand, has terminated the project with Sensile Medical to develop a micro pump for delivery of insulin to treat diabetes.
- SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment
- Sanofi terminates development project for micro pumps for patients with diabetes
- Further projects with pharma customers for various therapy areas for the micro pump started
"Our micro pump technology is highly advanced and very competitive. It can be used for a variety of treatments across medical conditions. The new SQ Innovation agreement illustrates the attractiveness of our micro pump technology. The pipeline of projects for the micro pump is very promising and we continue to see significant potential in this unique technology," said Dietmar Siemssen, CEO of Gerresheimer AG.
Sensile Medical, a Gerresheimer company, and SQ Innovation AG signed a partnership for the micro pump for the treatment of edema in heart failure for European and American markets. The market launch of the SQ Innovation product is to take place after completion of development and obtaining market authorization. Sensile Medical's micro pump for Parkin­son's treatment has already been approved for the European market in September 2018 and has been launched. A different project, the micro pump for delivery of insulin to treat diabetes, has been terminated by Sanofi for strategic reasons.
Gerresheimer has started several projects with pharma customers for usage of the micro pump in various therapy areas, which illustrate the future potential.
Information about SQ Innovation AG: http://furosemide.com
Gerresheimer AG Klaus-Bungert-Strasse 4 40468 Düsseldorf Germany
Contact: Jens Kürten Group Senior Director Communication & Marketing Phone: +49-211-6181-250 Telefax: +49-211-6181-241 jens.kuerten@gerresheimer.com [1] www.gerresheimer.com
1. http://www.gerresheimer.com/
Digital press kit: http://www.ots.at/pressemappe/PR9072/aom
 

Aktien auf dem Radar: Bawag , Warimpex , Porr , Marinomed Biotech , Addiko Bank , FACC , Zumtobel , Frequentis , Erste Group , Mayr-Melnhof , OMV , RBI , Verbund , Wienerberger , ATX , ATX Prime , Rosgix , Amag , SW Umwelttechnik , voestalpine , MTU Aero Engines , BMW , Infineon , Wirecard , Tomorrow Focus .


Random Partner

KTM
Die KTM Industries-Gruppe ist eine europäische Fahrzeug-Gruppe mit dem strategischen Fokus auf das globale Sportmotorradsegment und den automotiven high-tech Komponentenbereich. Mit ihren weltweit bekannten Marken KTM, Husqvarna Motorcycles, WP und Pankl zählt sie in ihren Segmenten jeweils zu den Technologie- und Marktführern.

>> Besuchen Sie 52 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER